Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.1.225

Factors Associated with Discontinuation of Complementary and Alternative Medicine among Korean Cancer Patients  

Kim, So Young (National Cancer Control Research Institute, National Cancer Center)
Kim, Kyung Sook (Korea Institute for Healthcare Accreditation)
Park, Jong Hyock (National Cancer Control Research Institute, National Cancer Center)
Shin, Ji-Yeon (National Cancer Control Research Institute, National Cancer Center)
Kim, Sung Kyeong (National Cancer Control Research Institute, National Cancer Center)
Park, Jae Hyun (Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine)
Park, Eun Cheol (Department of Preventive Medicine & Institute of Health Services Research, Yonsei University College of Medicine)
Seo, Hong Gwan (National Cancer Control Research Institute, National Cancer Center)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.1, 2013 , pp. 225-230 More about this Journal
Abstract
Objectives: The purpose of this study was to determine patient characteristics and other factors associated with discontinuation of complementary and alternative medicine (CAM) among cancer patients in Korea. Methods: A national, multicenter, cross-sectional survey of cancer patients was performed in which 674 of 2,661 patients were analyzed for their use of CAM after cancer diagnosis. Multiple logistic regression was used to identify the factors related to CAM discontinuation. Results: Among the surveyed cancer patients, 25.3% (674 of 2,661) had used CAM, whereas 38.3% (258 of 674) of those with CAM experience had discontinued CAM therapy. The most frequently used form of CAM was herbs (43.5%). The major reasons for the discontinuation of CAM included absence of effects (23.9%), financial burden (22.9%), and physician opposition (13.7%). Other factors associated with the discontinuation of CAM included metastatic cancer (OR = 2.06), a long duration of cancer treatment (OR = 3.34), dissatisfaction (OR = 4.34), and side effects (OR = 4.23) of CAM therapy. Conclusions: For cancer patients to correctly employ CAM therapy, increase their satisfaction, and reduce their side effects, efforts should be made to analyze the cost effectiveness of CAM, and valid information must be provided to physicians and cancer patients.
Keywords
Cancer; complementary; alternative medicine; Korea;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 National Center for Complementary and Alternative Medicine (NCCAM) (2012). What is complementary and alternative medicine?. http://nccam.nih.gov/health/whatiscam/ (24 Oct 2012, date last accessed).
2 Nazik E, Nazik H, Api M, et al (2012). Complementary and alternative medicine use by gynecologic oncology patients in Turkey. Asian Pac J Cancer Prev, 13, 21-5.   DOI   ScienceOn
3 Niggemann B, Gruber C (2003). Side-effects of complementary and alternative medicine. Allergy, 58, 707-16.   DOI   ScienceOn
4 Paltiel O, Avitzour M, Peretz T, et al (2001). Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol, 19, 2439-48.
5 Porter M, Kolva E, Ahl R, et al(2008). Changing patterns of CAM use among prostate cancer patients two years after diagnosis: reasons for maintenance or discontinuation. Complementary Therapies in Medicine, 16, 318-24.   DOI   ScienceOn
6 Saibul N, Shariff ZM, Rahmat A, et al(2012). Use of complementary and alternative medicine use among breast cancer survivors. Asian Pac J Cancer Prev, 13, 4081-6.   DOI   ScienceOn
7 Samur M, Bozcuk HS, Kara A, et al (2001). Factors associated with utilization of nonproven cancer therapies in Turkey. Support Care Cancer, 9, 452-8.   DOI   ScienceOn
8 Schmidt K, Ernst E (2004). Assessing websites on complementary and alternative medicine for cancer. Ann Oncol, 15, 733-42.   DOI   ScienceOn
9 Shin V, Chiang JYL, Chan A (2009). Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. Ann Oncol, 20, 752-7.   DOI   ScienceOn
10 Shumay DM, Maskarinec G, Gotay CC, et al(2002). Determinants of the degree of complementary and alternative medicine use among patients with cancer. The Journal of Alternative and Complementary Medicine, 8, 661-71.   DOI   ScienceOn
11 Siegel R, Naishadham D, Jemal A (2012). Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29.   DOI   ScienceOn
12 Stickel F, Patsenker E, Schuppan D (2005). Herbal hepatotoxicity. J Hepatology, 43, 901-10.   DOI   ScienceOn
13 Swarup AB, Barrett W, Jazieh AR (2006). The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol, 29, 468-73.   DOI   ScienceOn
14 Takahasi M, Kai I, Muto T (2012). Discrepancies Between Public Perceptions and Epidemiological Facts Regarding Cancer Prognosis and Incidence in Japan: An Internet Survey. Jpn J Clin Oncol doi:10.1093/jjco/hys125.   DOI
15 Tasaki K, Maskarinec G, Shumay DM, et al (2002). Communication between conventional medical doctors and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psycho-Oncology, 11, 212-20.   DOI
16 Yates JS, Mustian KM, Morrow GR, et al (2005). Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer, 13, 806-11.   DOI   ScienceOn
17 Er O, Mistik S, Ozkan M, et al(2008). Factors related to complementary/ alternative medicine use among cancer patients in central Anatolia. Tumori, 94, 833-7.
18 Harris P, Finlay IG, Cook A, et al (2003). Complementary and alternative medicine use by patients with cancer in Wales: a cross sectional survey. Complementary Therapies in Medicine, 11, 249-53.   DOI   ScienceOn
19 Hyodo I, Amano N, Eguchi K, et al (2005). Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol, 23, 2645-54.
20 Kim SG, Park EC, Park JH, et al (2007). Initiation and discontinuation of complementary therapy among cancer patients. J Clin Oncol, 25, 5267-74.   DOI   ScienceOn
21 Markman M (2003). Safety issues in using complementary and alternative medicine. J Clin Oncol, 20(18suppl), 39- 41.
22 Molassiotis A, Xu M (2004). Quality and safety issues of webbased information about herbal medicines in the treatment of cancer. Complementary Therapies in Medicine, 12, 217-27.   DOI   ScienceOn
23 Molassiotis A, Fernandez-Ortega P, Pud D, et al (2005). Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complementary Therapies in Medicine, 13, 251-7.   DOI   ScienceOn
24 Molassiotis A, Panteli V, Patiraki E, et al (2006). Complementary and alternative medicine use in lung cancer patients in eight European countries. Complementary Therapies in Clinical Practice, 12, 34-9.   DOI   ScienceOn
25 Montazeri A, Sajadian A, Ebrahimi M, et al (2007). Factors predicting the use of complementary and alternative therapies among cancer patients in Iran. European Journal of Cancer Care, 16, 144-9.   DOI   ScienceOn
26 Boon H, Stewart M, Kennard MA, et al (2000). Use of complementary/ alternative medicine by breast cancer survivors in Ontario. Prevalence and perceptions. J Clin Oncol, 18, 2515-21.
27 Choi JY, Chang YJ, Hong YS, et al (2012). Complementary and alternative medicine use among cancer patients at the end of life: Korea national study. Asian Pac J Cancer Prev, 13, 1419-24.   DOI   ScienceOn
28 Chung HJ, Kim MR, Bae JS, et al (2006). Complementary and alternative medicine in patients with breast cancer. J Breast Cancer, 9, 361-6.   DOI   ScienceOn
29 Crocetti E, Crotti N, Feltrin A, et al (1998). The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer, 34, 324-8.   DOI   ScienceOn
30 Donovan RJ, Jalleh G, Jones SC (2003). The word 'cancer': reframing the context to reduce anxiety arousal. Aust N Z Public Health, 27, 291-3.   DOI   ScienceOn
31 Downer SM, Cody MM, McCluskey P, et al (1994). Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ, 309, 86-9.   DOI   ScienceOn